Perelman School Of Medicine University Of Pennsylvania
Biologic use in psoriasis may increase PsA incidence vs. phototherapy, oral therapies
Patients with psoriasis who use biologics are more likely to develop psoriatic arthritis than those on other or no therapies, according to retrospective data published in the Annals of the Rheumatic Diseases.
'Build-up' of arthritis, axial symptom diagnoses often precede PsA diagnosis
Diagnoses of arthritis, axial symptoms and tendonitis or enthesitis often increase over time before a patient is finally diagnosed with psoriatic arthritis, according to data published in Arthritis Research & Therapy.
FDA approves avacopan for ANCA-associated vasculitis
The FDA has approved avacopan as an adjunctive treatment for adults with severe active ANCA-associated vasculitis, specifically granulomatosis with polyangiitis and microscopic polyangiitis, alongside standard therapy.
Older women with triple-negative breast cancer should undergo genetic testing
Genetic testing for hereditary cancer should be offered to all women aged older than 65 years with triple-negative or ER-negative breast cancer, according to study results published in Journal of Clinical Oncology.
Outcomes similar in Black, white patients with peripheral endovascular intervention
Among patients who underwent peripheral endovascular intervention, outcomes were similar between Black and white adults, though Black patients were less likely to have subsequent revascularization, according to data presented at VIVA 21.
NLA to unveil new scientific statements, focus on ‘lower is better’ for LDL management
The National Lipid Association Scientific Sessions, a hybrid meeting held Sept. 24-26, 2021, will include four featured sessions, updates on NLA scientific statements and numerous abstract presentations.
Three trials offer hope for 'challenging' steroid sparing in ANCA-associated vasculitis
A trio of recent clinical trials showed encouraging results for steroid-sparing strategies in ANCA-associated vasculitis, according to a presenter at the 2021 Congress of Clinical Rheumatology-West.
'Promising treatments' for Sjögren’s syndrome may enter clinical use in 3-5 years
It is likely that one or more “promising treatments” currently being investigated for Sjögren’s syndrome will come into use within the next 3 to 5 years, according to a presenter at the 2021 Congress of Clinical Rheumatology-West.
Researchers use ‘humanized’ CAR T cells to improve treatment durability for patients with ALL
The FDA approved the first chimeric antigen receptor therapy in 2017, authorizing tisagenlecleucel for treatment of children or young adults with relapsed or refractory B-cell acute lymphoblastic leukemia.
Cancer radiation treatment at high-volume centers associated with improved survival
Treatment at high-volume radiation therapy facilities correlated with improved survival among select patients with common malignancies, according to study results published in Cancer.